Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary Hemochromatosis
Background: The current treatment of hereditary hemochromatosis (HH) consists of performing periodic whole blood phlebotomies. Erythrocytapheresis (EA) can remove up to three times more red blood cells per single procedure and could thus have a clinical benefit. A prospective study of 30 consecutive...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karolinum Press
2012-01-01
|
| Series: | Acta Medica |
| Subjects: | |
| Online Access: | https://actamedica.lfhk.cuni.cz/55/4/0180/ |
| _version_ | 1818487327766347776 |
|---|---|
| author | Vít Řeháček Milan Bláha Hana Jiroušová Jitka Černohorská Petr Papoušek |
| author_facet | Vít Řeháček Milan Bláha Hana Jiroušová Jitka Černohorská Petr Papoušek |
| author_sort | Vít Řeháček |
| collection | DOAJ |
| description | Background: The current treatment of hereditary hemochromatosis (HH) consists of performing periodic whole blood phlebotomies. Erythrocytapheresis (EA) can remove up to three times more red blood cells per single procedure and could thus have a clinical benefit. A prospective study of 30 consecutive cases of HH were included in a periodic EA program. Methods and patients: EA were performed using a discontinuous flow cell separators. The protocol consisted of a bimonthly EA until normalization of the serum ferritin was reached. The aim was to reduce the total erythrocyte volume by 25–35%, eventually, to adjust the amount so that hematocrit would not drop below 0.25. Results: 530 ± 101 ml of erythrocytes were removed (median 517, range 116–761 ml). Iron depletion (ferritin < 20 μg/l) was achieved in all patients after a mean 6.9 ± 7.6 months, median 5 months, range 1–36 months and a mean 14 EA sessions. The procedures were well tolerated and there were no severe side-effects. Conclusions: We conclude that HH patients treated with EA achieved iron depletion quickly under good conditions of tolerance. The efficacy, speed, tolerability, and more favorable schedule of an EA program facilitate treatment of HH. |
| first_indexed | 2024-12-10T16:36:23Z |
| format | Article |
| id | doaj.art-41dcbf0180b44a39828c5202791cc2e0 |
| institution | Directory Open Access Journal |
| issn | 1211-4286 1805-9694 |
| language | English |
| last_indexed | 2024-12-10T16:36:23Z |
| publishDate | 2012-01-01 |
| publisher | Karolinum Press |
| record_format | Article |
| series | Acta Medica |
| spelling | doaj.art-41dcbf0180b44a39828c5202791cc2e02022-12-22T01:41:23ZengKarolinum PressActa Medica1211-42861805-96942012-01-0155418018510.14712/18059694.2015.43Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary HemochromatosisVít Řeháček0Milan Bláha1Hana Jiroušová2Jitka Černohorská3Petr Papoušek4Charles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Czech Republic: Transfusion Department4th Department of Medicine, Hematology, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec KrálovéCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Czech Republic: Transfusion DepartmentCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Czech Republic: Transfusion DepartmentCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Czech Republic: Transfusion DepartmentBackground: The current treatment of hereditary hemochromatosis (HH) consists of performing periodic whole blood phlebotomies. Erythrocytapheresis (EA) can remove up to three times more red blood cells per single procedure and could thus have a clinical benefit. A prospective study of 30 consecutive cases of HH were included in a periodic EA program. Methods and patients: EA were performed using a discontinuous flow cell separators. The protocol consisted of a bimonthly EA until normalization of the serum ferritin was reached. The aim was to reduce the total erythrocyte volume by 25–35%, eventually, to adjust the amount so that hematocrit would not drop below 0.25. Results: 530 ± 101 ml of erythrocytes were removed (median 517, range 116–761 ml). Iron depletion (ferritin < 20 μg/l) was achieved in all patients after a mean 6.9 ± 7.6 months, median 5 months, range 1–36 months and a mean 14 EA sessions. The procedures were well tolerated and there were no severe side-effects. Conclusions: We conclude that HH patients treated with EA achieved iron depletion quickly under good conditions of tolerance. The efficacy, speed, tolerability, and more favorable schedule of an EA program facilitate treatment of HH.https://actamedica.lfhk.cuni.cz/55/4/0180/Hereditary hemochromatosisHFE-genePhlebotomyTherapeutic Erythrocytapheresis |
| spellingShingle | Vít Řeháček Milan Bláha Hana Jiroušová Jitka Černohorská Petr Papoušek Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary Hemochromatosis Acta Medica Hereditary hemochromatosis HFE-gene Phlebotomy Therapeutic Erythrocytapheresis |
| title | Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary Hemochromatosis |
| title_full | Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary Hemochromatosis |
| title_fullStr | Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary Hemochromatosis |
| title_full_unstemmed | Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary Hemochromatosis |
| title_short | Therapeutic Erythrocytapheresis in the Initial Treatment of Hereditary Hemochromatosis |
| title_sort | therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis |
| topic | Hereditary hemochromatosis HFE-gene Phlebotomy Therapeutic Erythrocytapheresis |
| url | https://actamedica.lfhk.cuni.cz/55/4/0180/ |
| work_keys_str_mv | AT vitrehacek therapeuticerythrocytapheresisintheinitialtreatmentofhereditaryhemochromatosis AT milanblaha therapeuticerythrocytapheresisintheinitialtreatmentofhereditaryhemochromatosis AT hanajirousova therapeuticerythrocytapheresisintheinitialtreatmentofhereditaryhemochromatosis AT jitkacernohorska therapeuticerythrocytapheresisintheinitialtreatmentofhereditaryhemochromatosis AT petrpapousek therapeuticerythrocytapheresisintheinitialtreatmentofhereditaryhemochromatosis |